SEARCH

SEARCH BY CITATION

References

  • 1
    Olivieri NF . The beta-thalassemias. N Engl J Med 1999;341:99109.
  • 2
    Forget B . Hematology: Basic principles and practice. Chapter 41. New York: Churchill Livingstone, Thalassemia syndromes, 2000:485525.
  • 3
    Rund D , Rachmilewitz E . Beta-thalassemia. N Engl J Med 2005;353:113546.
  • 4
    Borgna-Pignatti C , Cappellini MD , De Stefano P , et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:37337.
  • 5
    Berdoukas V , Chouliaras G , Moraitis P , Zannikos K , Berdoussi E , Ladis V . The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009;11(Suppl 20):111.
  • 6
    Ladis V , Chouliaras G , Berdoukas V , Moraitis P , Zannikos K , Berdoussi E , Kattamis C . Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol, 2010;85:33544.
  • 7
    Coresh J , Selvin E , Stevens LA , Manzi J , Kusek JW , Eggers P , Van Lente F , Levey AS . Prevalence of chronic kidney disease in the United States. JAMA 2007;298:203847.
  • 8
    Richards N , Harris K , Whitfield M , O'Donoghue D , Lewis R , Mansell M , Thomas S , Townwnd J , Marcelli D . Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 2008;23:54955.
  • 9
    Richards N , Harris K , Whitfield M , O'Donoghue D , Lewis R , Mansell M , Thomas S , Townend J , Eames M , Marcelli D . The impact of population-based identification of chronic kidney disease using estimated glomerular filtration rate (eGFR) reporting. Nephrol Dial Transplant 2008;23:55661.
  • 10
    Cheung CK , Bhandari S . Perspectives on eGFR reporting from the interface between primary and secondary care. Clin J Am Soc Nephrol 2009;4:25860.
  • 11
    Cox HJ , Bhandari S , Rigby AS , Kilpatrick ES . Mortality at low and high estimated glomerular filtration rate values: a ‘U’ shaped curve. Nephron Clin Pract 2008;110:c6772.
  • 12
    Couser WG , Riella MC . World Kidney Day 2011: protect your kidneys, save your heart. Med J Aust 2011;194:2257.
  • 13
    Astor BC , Levey AS , Stevens LA , Van Lente F , Selvin E , Coresh J . Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol 2009;20:221422.
  • 14
    Papassotiriou I , Margeli A , Hantzi E , Delaporta P , Sergounioti A , Goussetis E , Ladis V , Kattamis A . Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood Cells Mol Dis 2010;44:1525.
  • 15
    Hallan SI , Ritz E , Lydersen S , Romundstad S , Kvenild K , Orth SR . Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009;20:106977.
  • 16
    Lambers Heerspink HJ , Gansevoort RT , Brenner BM , Cooper ME , Parving HH , Shahinfar S , de Zeeuw D . Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010;21:135560.
  • 17
    Di Iorio BR , Aucella F , Stallone C , Bellizzi V . Thalassaemia minor: national survey of uraemic patients under substitutive treatment. G Ital Nefrol 2002;19:28693.
  • 18
    Quinn CT , Johnson VL , Kim H-Y . Renal dysfunction in patients with thalassaemia. Br J Haematol 2011;153:1117.
  • 19
    Aldudak B , Karabay Bayazit A , Noyan A , Ozel A , Anarat A , Sasmaz I , Kilinc Y , Gali E , Anarat R , Dikmen N . Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol 2000;15:10912.
  • 20
    Mastrangelo F , Lopez T , Rizzelli S , Manisco G , Corliano C , Alfonso L . Function of the kidney in adult patients with Cooley's disease. A preliminary report. Nephron 1975;14:22936.
  • 21
    Ali D , Mehran K , Moghaddam AG . Comparative evaluation of renal findings in Beta-thalassemia major and intermedia. Saudi J Kidney Dis Transpl 2008;19:2069.
  • 22
    Mohkam M , Shamsian BS , Gharib A , Nariman S , Arzanian MT . Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatr Nephrol 2008;23:9716.
  • 23
    Smolkin V , Halevy R , Levin C , Mines M , Sakran W , Ilia K , Koren A . Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol 2008;23:184751.
  • 24
    Koren G , Bentur Y , Strong D , Harvey E , Klein J , Baumal R , Spielberg SP , Freedman MH . Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989;143:107780.
  • 25
    Koliakos G , Papachristou F , Koussi A , Perifanis V , Tsatra I , Souliou E , Athanasiou M . Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol 2003;25:1059.
  • 26
    Lapatsanis P , Sbyrakis S , Vertos C , Karaklis BA , Dosiadis S . Phosphaturia in thalassemia. Pediatrics 1976;58:88592.
  • 27
    Sumboonnanonda A , Malasit P , Tanphaichitr VS , Ong-ajyooth S , Sunthornchart S , Pattanakitsakul S , Petrarat S , Assateerawatt A , Vongjirad A . Renal tubular function in beta-thalassemia. Pediatr Nephrol 1998;12:2803.
  • 28
    Grossman H , Dische MR , Winchester PH , Canale V . Renal enlargement in thalassemia major. Radiology 1971;100:6458.
  • 29
    Harada T , Ozono Y , Myazaki M , Yamaguchi K , Kanamoto Y , Hara K , Taguchi T . Association of IgA nephropathy and beta-thalassemia. Clin Nephrol 1994;41:1812.
  • 30
    Shah SV , Baliga R , Fonseca VA , Rajapurkar M . Oxidants in chronic kidney disease. J Am Soc Nephrol 2007;18:1628.
  • 31
    Malik AB , Vamferdam R , Justus R , Ounpraseuth S . Iron chelation with DFP for diabetic nephropathy in the db/db mouse. J Am Soc Nephrol 2011;21:710A,2567. [Abstract].
  • 32
    Agarwal R . Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 2006;69:125963.
  • 33
    Landing BH , Gonick HC , Nadorra RL , Hyman CB , Wells TR , Villarreal-Engelhardt G , Mersch J , Agness CL . Renal lesions and clinical findings in thalassemia major and other chronic anemias with hemosiderosis. Pediatr Pathol 1989;9:479500.
  • 34
    Zhou XJ , Laszik Z , Wang XQ , Silva FG , Vaziri ND . Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 2000;80:190514.
  • 35
    Sadeghi-Bojd S , Hashemi M , Karimi M . Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran. Singapore Med J 2008;49:4102.
  • 36
    Jalali A , Khalilian H , Ahmadzadeh A , Sarvestani S , Rahim F , Zandian K , Asar S . Renal function in transfusion-dependent pediatric beta-thalassemia major patients. Hematology 2011;16:24954.
  • 37
    Halliwell B , Gutteridge JM . Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:185.
  • 38
    Kassab-Chekir A , Laradi S , Ferchichi S , Haj Khelil A , Feki M , Amri F , Selmi H , Bejaoui M , Miled A . Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta 2003;338:7986.
  • 39
    Baliga R , Ueda N , Walker PD , Shah SV . Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999;31:97197.
  • 40
    Ueda N , Mayeux PR , Baliga R , Shah SV . Oxidant mechanisms in acute renal failure. In: Molitoris B , Finn W , eds. Acute Renal Failure: A Companion to Brenner & Rector's The Kidney. Philadelphia: W. B. Saunders Company; 2001: 6077.
  • 41
    Mehta RL , Kellum JA , Shah SV , et al. Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
  • 42
    Agarwal R , Leehey DJ , Olsen SM , Dahl NV . Proteinuria induced by parenteral iron in chronic kidney disease–a comparative randomized controlled trial. Clin J Am Soc Nephrol, 2011;6:11421.
  • 43
    Rajapurkar M , Gang S , Hegde U , Gohel K , Shah SV . Study of urinary catalytic (bleomycin-detectable) iron following radiocontrast exposure in healthy kidney donors. J Am Soc Nephrol 2007;18:575A.
  • 44
    Hanss BG , Valencia SH , Shah SV , Vari RC . The iron chelator deferoxamine prevents contrast media induced acute renal failure in the rabbit. J Am Soc Nephrol 1990;1:612.
  • 45
    Schein A , Enriquez C , Coates TD , Wood JC . Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging 2008;28:698704.
  • 46
    Maier-Redelsperger M , Levy P , Lionnet F , Stankovic K , Haymann J-P , Lefevre G , Avellino V , Perol JP , Girot R , Elion J . Strong association between a new marker of hemolysis and glomerulopathy in sickle cell anemia. Blood Cells Mol Dis 2010;45:28992.
  • 47
    Ferrari P , Kulkarni H , Dheda S , Betti S , Harrison C , St Pierre TG , Olynyk JK . Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:7783.
  • 48
    Nagababu E , Gulyani S , Earley CJ , Cutler RG , Mattson MP , Rifkind JM . Iron-deficiency anaemia enhances red blood cell oxidative stress. Free Radical Res 2008;42:8249.
  • 49
    Kaissling B , Piess S , Rinne B , Le Hir M . Effects of anemia on morphology of rat renal cortex. Am J Physiol 1993;264(4 Pt 2):F60817.
  • 50
    Olivieri NF , Brittenham GM . Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89(Suppl 3):73961.
  • 51
    Brittenham GM , Nathan DG , Olivieri NF , Pippard MJ , Weatherall DJ Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003;361:183; author reply 183–4.
  • 52
    Hoffbrand AV , Al-Refaie F , Davis B , Siritanakatkul N , Jackson BF , Cochrane J , Prescott E , Wonke B . Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295300.
  • 53
    Cappellini MD , Cohen A , Piga A , et al. Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassaemia. Blood 2006;107:345562.
  • 54
    Rafat C , Ribeil JA . Fanconi Syndrome due to deferasirox. Am J Kidney Dis 2009;54:9314.
  • 55
    Yacobovich J , Stark P , Barzilai-Birenbaum S , Krause I , Pazgal I , Yaniv I , Tamary H . Acquired proximal renal tubular dysfunction in -thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 2010;32:5647.
  • 56
    Batey R , Scott J , Jain S , Sherlock S . Acute renal insufficiency occurring during intravenous desferrioxamine therapy. Scand J Haematol 1979;22:2779.
  • 57
    Cianciulli P , Sollecito D , Sorrentino F , Forte L , Palombi M , Papa G , Meloni C , Taccone GM , Casciani CU . Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therap. Kidney Int 1994;396:46770.
  • 58
    Cianciulli P , Sorrentino F , Forte L , Palombi M , Papa G , Meloni C , Taccone GM , Casciani CU Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. Haematologica 1992;77:5145.
  • 59
    Li Volti S , Di Gregorio F , Schiliro G . Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1990;144:106970.
  • 60
    Li Volti S , Maccarone C , Li Volti G , Romeo MA . Acute renal failure following deferoxamine overdose. Pediatr Nephrol 2003;18:10789.
  • 61
    Prasannan L , Flynn JT , Levine JE . Acute renal failure following deferoxamine overdose. Pediatr Nephrol 2003;18:2835.
  • 62
    Brosnahan G , Gokden N , Swaminathan S . Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant 2008;23:33568.
  • 63
    Clajus C , Becker JU , Stichtenoth DO , Wortmann J , Schwarz A , Kielstein JT . Acute kidney injury due to deferoxamine in a renal transplant patient. Nephrol Dial Transplant 2008;23:10614.
  • 64
    Cappellini MD , Porter J , El-Beshlawy A , et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:55766.
  • 65
    Adamkiewicz TV , Erkovitch M , Krishnan C , Polsinelli C , Kermack D , Olivieri NF . Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin Infect Dis 1998;27:13626.
  • 66
    Chan GC-F , Chan S , Ho P-L , Ha S-Y . Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin 2009;33:35260.
  • 67
    Robins-Browne RM , Prpic JK . Effects of iron and desferrioxamine on infections with Yersinia enterocolitica . Infect Immun 1985;47:7749.
  • 68
    Bhandari S . Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Front Biosci 2011;16:136487.
  • 69
    Aydinok Y , Unal S , Oymak Y , Vergin C , Türker ZD , Yildiz D , Yesilipek A Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload. Eur J Haematol 2012;88:431438.
  • 70
    Bhandari S , Daar SF , Panjwani VK . Natural history of iron chelation toxicity in patients with thalassaemia major and intermedia in Oman. J Am Soc Nephrol 2011;22:870A,2349. [Abstract].
  • 71
    Galanello R . Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag 2007;3:795805.
  • 72
    El Alfy M , Sari TT , Lee CL , Tricta F , El-Beshlawy A . The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol 2010;32:6015.
  • 73
    Papadopoulos N , Vasiliki A , Aloizos G , Tapinis P , Kikilas A . Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother 2010;44:21921.
  • 74
    Kontoghiorghes GJ . Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf 2010;9:63341.
  • 75
    Vlachaki E , Chatzinikolaou BE , Klonizakis F , Tsapas A . Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia? Angiology 2011;62:3468.
  • 76
    Rheault MN , Bechtel H , Neglia JP , Kashtan CE . Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer 2011;56:6746.
  • 77
    Chandra J , Chaudhary H , Pemde H , Singh V , Dutta AK . Safety and efficacy of deferasirox in multitransfused Indian children with -thalassaemia major. Ann Trop Paediatr 2011;31:4751.
  • 78
    Huang X-P , Thiessen JJ , Spino M , Templeton DM . Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy. Int J Hematol 2010;91:40112.
  • 79
    Taher A , Cappellini MD , Vichinsky E , Galanello R , Piga A , Lawniczek T , Clark J , Habr D , Porter JB . Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009;147:7529.
  • 80
    Taher A , Elalfy MS , Al Zir K , Daar S , Al Jefri A , Habr D , Kriemler-Krahn U , El-Ali A , Roubert B , El-Beshlawy A . Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol 2011;87:35565.
  • 81
    Cappellini MD , Bejaoui M , Agaoglu L , et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011;118:88493.
  • 82
    Cappellini MD , Taher A . Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol 2009;122:16573.
  • 83
    Piga A , Galanello R , Forni GL , et al. Andomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:87380.
  • 84
    Bergeron R , Treilf R , Wingand J , Vinson J . A comparative evaluation of iron clearance models. Ann N Y Acad Sci 1990;6:37893.
  • 85
    Tanji K , Imaizumi T , Matsumiya T , et al. Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochim Biophys Acta 2001;1530:22735.
  • 86
    Piga A . Renal Blood flow in deferasirox therapy. TIFF, 2011. abstract op03.
  • 87
    Holtkamp FA , e Zeeuw D , Thomas MC , Cooper ME , de Graeff PA , Hillege HJL , Parving HH , Brenner BM , Shahinfar S , Lambers HHJ . An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int, 2011;80:2827.
  • 88
    Sanchez-Gonzalez P , Lopez-Hernandez F , Morales AI , Macías-Nuñez JF , López-Novoa JM . Effects of deferasirox on renal function and renal epithelial cell death. Toxicol Lett 2011;203:15461.
  • 89
    Zager RA , Johnson AM , Hanson SY , Wasse H . Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90103.
  • 90
    Gao X , Qian M , Campian JL , Marshall J , Zhou Z , Roberts AM , Kang YJ , Prabhu SD , Sun XF , Eaton JW . Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Free Radical Biol Med 2010;49:4017.
  • 91
    Rao M , Li L , Demello C , Guo D , Jaber BL , Pereira BJG , Balakrishnan VS , on behalf of the HEMO study Group. Mitochondrial DNA injury and mortality in hemodialysis patients. J Am Soc Nephrol 2009;20:18996.
  • 92
    Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:207381.
  • 93
    Ninomiya T , Perkovic V , de Galan BE , et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:181321.
  • 94
    Brittenham GM . Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:14656.
  • 95
    Farmaki K , Angelopoulos N , Anagnostopoulos G , Gotsis E , Rombopoulos G , Tolis G . Effect of enhanced iron chelation therapy on glucose metabolism in patients with β-thalassaemia major. Br J Haematol 2006;134:43844.
  • 96
    Farmaki K , Tzoumari I , Pappa C . Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis 2011;47:3340.
  • 97
    Alpendurada F , Smith G , Carpenter JP , Nair S , Tanner M , Banya W , Dessi C , Galanllo R , Walker J , Pennell D , Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson 2012;14:8.
  • 98
    Balocco M , Carrara P , Pinto V , Forni GL . Daily alternating deferasirox and deferiprone therapy for “hard-to-chelate” β-thalassemia major patients. Am J Hematol 2010;85:4601.